MediTox

… You develop the ideas, we can help you navigate through challenges of preclinical research

Our focus

MediTox is a GLP-certified CRO with more than 25 years’ experience in preclinical toxicology and extensive experience with variety of compounds and therapeutic areas, capable to conduct studies in full compliance with GLP standards and other international guidelines (EMA/ICH, VICH, OECD, FDA, ISO10993), providing core range of nonclinical studies enabling IND/registration for human drugs, biologicals and safety (TAS/BEQ/efficacy) studies for registration of veterinary drugs.
One of the few facilities in Europe using cats as target animals for the testing of veterinary drugs.

Whether you are just starting out or dealing with a specific issue, we are ready to discuss everything with you and propose a set of studies.
Quality
Compliance with OECD TG, EMA/ICH, VICH, ISO 10993
Human health
Compliance with OECD TG, EMA/ICH, EFSA, ISO 10993
Animal health
Compliance with VICH, EFSA
Medical device
Compliance with OECD TG, ISO 10993

Mission & vision

We are dedicated to being a reliable partner for our clients in bringing innovative ideas to market, with unwavering adherence to scientific integrity and business ethics.

Our goal is to be recognized as a trusted and respected partner in the field of drug development — known for our strong team of top-tier experts, high professional standards, flexibility, and a personalized, friendly approach to every client.

We strive for excellence in both operations and service by expertise. Through close collaboration with the scientific community, we ensure the highest quality of our services and continually work to enhance client satisfaction.

Key Highlights

  • Extensive expertise in non-rodent toxicology
  • Validated models for human diseases, including influenza, chronic glaucoma, osteoarthritis
  • One of the few facilities in Europe offering TAS and bioequivalence studies in cats
  • Dedicated team of experts specialized in advanced veterinary surgical procedures
  • Trusted research partner in multiple awarded European grant projects

Our team

Board of Directors

Expert Team

Business Development

News & Events

The fastest study isn’t always the shortest one

Everyone wants to accelerate drug development. But in preclinical research, the real bottlenecks are often avoidable: • Protocol amendments after study initiation • Delays in test article supply • Analytical methods that are not ready • Unclear study objectives Removing these obstacles often saves more time than trying to shorten the experimental phase itself. Efficiency begins with preparation—not with rushing execution.

MediTox s.r.o. is heading to BIOEurope 2026!

Join us in Cologne, Germany, November 9–11, and meet our team at Booth 7-11. Let’s connect, exchange ideas, and explore new opportunities for collaboration. Partnering opens on September 28, 2026 — book a meeting with us through the BIO-Europe partnering system. We look forward to seeing you in Cologne!

MediTox at Nordic Life Science Days 2026

MediTox was pleased to participate in Nordic Life Science Days (NLS Days) 2026 in Stockholm. It was a highly inspiring event, full of new ideas, interesting discussions, and valuable opportunities for collaboration. We had a busy schedule of productive partnering meetings and enjoyed connecting with both new and familiar faces from across the life sciences community. From our perspective, NLS Days 2026 was a great success, and we look forward to turning these discussions into future collaborations.

Address

MediTox s.r.o.,
Pod Zámkem 279,
281 25 Konárovice, Czech Republic

company ID

25926713

vat number

CZ25926713
Would you like to ask a question? Contact us:
By submitting the form, you agree to the processing of your personal data.

Curriculum vitae

Načítám životopis…